Immunosuppressants drugs - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.90 [0.64, 1.26]< 128%8 studies (10/-)73.7 %some concernnot evaluable moderatecrucial-
death or transfer to ICU 0.93 [0.87, 0.99]< 10%1 study (-/1)98.6 %NAnot evaluable crucial-
deaths 0.87 [0.70, 1.09]< 116%12 studies (17/-)89.0 %some concernlow moderatecrucial-
deaths (time to event analysis only) 1.04 [0.78, 1.38]< 10%3 studies (3/-)39.8 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.56 [0.26, 1.20]< 10%1 study (1/-)93.1 %NAnot evaluable important-
clinical improvement 1.38 [1.04, 1.82]> 140%6 studies (7/-)98.8 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.97 [0.95, 4.09]> 10%1 study (2/-)96.6 %NAnot evaluable important-
clinical improvement (28-day) 1.33 [0.95, 1.87]> 10%4 studies (4/-)95.3 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.09 [0.87, 1.35]> 10%2 studies (2/-)76.9 %some concernnot evaluable moderateimportant-
death or ventilation 0.96 [0.65, 1.43]< 126%3 studies (3/-)57.8 %some concernnot evaluable moderateimportant-
hospital discharge 0.97 [0.79, 1.20]> 10%1 study (1/-)38.9 %NAnot evaluable important-
mechanical ventilation 0.36 [0.09, 1.48]< 131%3 studies (4/-)92.1 %some concernnot evaluable moderateimportant-
ICU admission 0.48 [0.25, 0.94]< 10%1 study (2/-)98.4 %NAnot evaluable non important-
recovery 1.30 [0.64, 2.66]> 19%2 studies (2/-)76.5 %lownot evaluable highnon important-

safety endpoints 00

related AE (TRAE) 1.26 [0.14, 11.07]< 10%2 studies (2/-)41.9 %some concernnot evaluable moderateimportant-
serious adverse events 0.99 [0.77, 1.28]< 116%6 studies (6/-)52.7 %some concernserious moderateimportant-
superinfection 3.27 [1.66, 6.43]< 10%1 study (-/1)0.0 %NAnot evaluable important-
acute kidney injury 0.43 [0.14, 1.34]< 10%1 study (-/1)92.7 %NAnot evaluable non important-
adverse events 1.14 [0.87, 1.50]< 122%7 studies (7/-)16.7 %some concernnot evaluable moderatenon important-
arrhythmia 0.16 [0.03, 0.90]< 10%1 study (-/1)98.1 %NAnot evaluable non important-
elevated liver enzymes 0.52 [0.18, 1.51]< 10%1 study (-/1)88.5 %NAnot evaluable non important-
Myocardial infarction 0.87 [0.19, 3.92]< 10%1 study (-/1)57.2 %NAnot evaluable non important-
venous thromboembolism 5.23 [0.42, 65.62]< 10%1 study (-/1)10.2 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.